Skip to content
10-Q

Quarterly Report

Krystal Biotech, Inc. KRYS

0001711279-26-000043

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 29.48M sh
Shares Diluted Q1 2026 · Mar 31, 2026 30.51M sh
Shares Diluted Q1 2026 · Mar 31, 2025 29.87M sh
Capex Q1 2026 · Mar 31, 2026 $7.15M
Capex Q1 2026 · Mar 31, 2025 $6.2M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $80.38M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $30.97M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $501.31M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $496.3M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.28B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.22B
Stockholders Equity Q1 2026 · Mar 31, 2025 $984.67M
Stockholders Equity Q1 2026 · Dec 31, 2024 $946.38M
Current Liabilities Q1 2026 · Mar 31, 2026 $107.8M
Current Liabilities Q1 2026 · Dec 31, 2025 $102.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $120.24M
Total Liabilities Q1 2026 · Dec 31, 2025 $114.23M
Current Assets Q1 2026 · Mar 31, 2026 $1.02B
Current Assets Q1 2026 · Dec 31, 2025 $1.02B
Total Assets Q1 2026 · Mar 31, 2026 $1.4B
Total Assets Q1 2026 · Dec 31, 2025 $1.33B
Eps Diluted Q1 2026 · Mar 31, 2026 $1.83
Eps Diluted Q1 2026 · Mar 31, 2025 $1.20
Eps Basic Q1 2026 · Mar 31, 2026 $1.91
Eps Basic Q1 2026 · Mar 31, 2025 $1.24
Sga Expense Q1 2026 · Mar 31, 2026 $41.01M
Sga Expense restated Q1 2026 · Mar 31, 2025 $32.65M
Rd Expense Q1 2026 · Mar 31, 2026 $15.33M
Rd Expense restated Q1 2026 · Mar 31, 2025 $14.26M
Net Income Q1 2026 · Mar 31, 2026 $55.93M
Net Income Q1 2026 · Mar 31, 2025 $35.73M
Operating Income Q1 2026 · Mar 31, 2026 $53.69M
Operating Income restated Q1 2026 · Mar 31, 2025 $36.25M
Revenue Q1 2026 · Mar 31, 2026 $116.36M
Revenue Q1 2026 · Mar 31, 2025 $88.18M